Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine

Leukemia Research

Volumn 23, Issue 8, 1999, Pages 695-700

  Raanani, Pia ^a   Shpilberg, Ofer ^a   Gillis, Shmuel ^c   Avigdor, Abraham ^a   Hardan, Izhar ^a   Berkowicz, Miriam ^a   Sofer, Orit ^a   Lossos, Izidore ^c   Chetrit, Angela ^b   Ben Yehuda, Dina ^c   Ben Bassat, Isaac ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Acute leukemia; HIDAC; Mitoxantrone; Refractory; Relapsed; Salvage

Indexed keywords

CYTARABINE; MITOXANTRONE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; DIARRHEA; DRUG TOXICITY; FEMALE; FEVER; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RELAPSE; SALVAGE THERAPY; SKIN TOXICITY; VOMITING;

ACUTE DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MITOXANTRONE; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032767878     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00078-8     Document Type: Article

References (35)

1. Cline M.J., Golde D.W., Billing R.J., Groopman J.E., Zighelboim J., Gale R.P. Acute leukemia: biology and treatment. Ann. Intern. Med. 91:1979;758.
2. Cassileth P.A., Begg C.B., Bennett J.M., Bozdech M., Kahn S.B., Weiler C., Glick J.H. A randomized study of the efficacy of consolidation therapy in acute nonlymphocytic leukemia. Blood. 63:1984;843.
3. Champlin R., Gale R.P. Acute myelogenous leukemia: recent advances in therapy. Blood. 69:1987;1551.
4. Gale R.P., Foon K.A. Therapy of acute myelogenous leukemia. Semin. Hematol. 24:1987;40.
5. Champlin R., Gajewski J., Nimer S., Vollset S., Landaw E., Winston D. et al. Postremission chemotherapy for adults with acute myelogenous leukemia: Improved survival with high dose cytarabine and daunorubicin consolidation treatment. J. Clin. Oncol. 8:1990;1199.
6. Buchner T., Hiddemann W. Treatment strategies in acute myeloid leukemia (AML). First-line chemotherapy. Blut. 60:1990;61.
7. Schiller G. Treatment of resistant acute myeloid leukemia. Blood Rev. 5:1991;220.
8. Welborn J.L. Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am. J. Hematol. 45:1994;341.
9. Hilbe W., Thaler J., Eisterer W., Ludescher C., Niederwieser D. Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). Leuk. Res. 18:1994;655.
10. Herzig R.H., Wolff S.N., Lazarus H.M., Phillips G.L., Karanes C., Herzig G.P. High dose cytosine arabinoside therapy for refractory leukemia. Blood. 62:1983;361.
11. Hines J.D., Oken M.M., Mazza J.J., Keller A.M., Streeter R.R., Glick J.H. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J. Clin. Oncol. 2:1984;545.
12. Herzig R.H., Lazarus H.M., Wolff S.N., Phillips G.L., Herzig G.P. High dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission induction of acute nonlymphoblastic leukemia. J. Clin. Oncol. 3:1985;992.
13. Gore M., Powles R., Lakhani A., Milan S., Maitland J., Goss G., Nandi A. et al. Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide. Cancer Chemother. Pharmacol. 23:1989;373.
14. Estey E.H., Keating M.J., McCredie K.B., Bodey G.P., Freireich E.J. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat. Report. 67:1983;389.
15. Prentice H.G, Robbins G., Ma D.D.F, Ho A.D. Mitoxantrone in relapsed and refractory acute leukemia. Semin. Oncol. 11:1984;32.
16. Ehninger G., Ho A.D., Meyer P., Mjaaland I., Ostendorf P., Seither E. Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Onkologie. 8:1985;146.
17. Feldman E.J., Alberts D.S., Arlin Z., Ahmed T., Mittelman A., Baskind P. et al. Phase I clinical and pharmacokinetic evaluation of high dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J. Clin. Oncol. 11:1993;2002.
18. Arlin Z.A., Feldman E.J., Finger L.R., Ahmed T., Mittelman A., Cook P. et al. Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia. 5:1991;712.
19. Keating M.J., Kantarjian H., Smith T.L., Estey E., Walters R., Andersson B. et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J. Clin. Oncol. 7:1989;1071.
20. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207.
21. Hiddemann W., Kreutzmann H., Straif K., Ludwig W.D., Mertelsmann R., Planker M. et al. High dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin. Oncol. 14(Suppl 1):1987;73.
22. Hiddemann W., Buchner T., Heil G., Schumacher K., Diedrich H., Maschmeyer G. et al. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia. 4:1990;637.
23. Feldman E.J., Seiter K., Damon L., Linker C., Rugo H., Reis C. et al. A randomized trial of high vs. standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia. 11:1997;485.
24. Kern W., Schleyer E., Unterhalt M., Wormann B., Buchner T., Hiddemann W High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer. 79:1997;59.
25. Weiss M., Maslak P., Feldman E., Berman E., Bertino J., Gee T. et al. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J. Clin. Oncol. 14:1996;2480.
26. Arlin Z.A., Ahmed T., Mittelman A., Feldman E., Mehta R., Weinstein P. et al. A new regimen of amsacrine with high dose cytarabine is safe and effective therapy for acute leukemia. J. Clin. Oncol. 5:1987;371.
27. Lejeune C., Tubiana N., Gastaut J.A., Maraninchi D., Richard B., Launay M.C. et al. High dose cytosine arabinoside and mitoxantrone in previously treated acute leukemia patients. Eur. J. Haematol. 44:1990;240.
28. Keskin A., Tombuloglu M., Atamer M.A., Buyukkececi F. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia. Acta Haematol. 92:1994;14.
29. Kantarjian H.M., Walters R.L., Keating M.J., Estey E.H., O'Brien S., Schachner J. et al. Mitoxantrone and high dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukaemia. Cancer. 65:1990;5.
30. Amadori S., Arcese W., Isacchi G., Meloni G., Petti M.C., Monarca B. et al. Mitoxantrone, etoposide and intermediate dose cytarabine. An effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J. Clin. Oncol. 9:1991;1210.
31. Sierra J., Granena A., Bosch F., Carreras E., Marti J.M., Urbano-Ispizua A. et al. Mitoxantrone and intermediate dose cytosine arabinoside for poor risk acute leukemias: response to treatment and factors influencing outcome. Hematol. Oncol. 10:1992;301.
32. Larson R.A., Day R.S., Azarnia N., Bennett J.M., Browman G., Goldberg J. et al. The selective use of AMSA following high dose cytarabine in patients with acute myeloid leukemia in relapse: a leukemia intergroup study. Br. J. Haematol. 82:1992;337.
33. Damon L.E., Rugo H.S., Ries C.A., Linker C.A. Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. Leukemia. 8:1994;535.
34. Damon L.E., Rugo H.S., Ries C.A., Linker C.A. Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. Bone Marrow Transpl. 17:1996;93.
35. Davis C.L., Rohatiner A.Z.S., Lim J., Whelan J.S., Oza A.M., Amess J. et al. The management of recurrent acute myelogenous leukaemia at a single center over a fifteen year period. Br. J. Haematol. 83:1993;404.